Common Supplement PQQ Found to Block Cancer-Driving Enzyme in Lymphoma Cells
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
Summary
Researchers screened over 2,000 compounds and discovered that pyrroloquinoline quinone (PQQ) — a popular antioxidant supplement — potently inhibits PRC2, an enzyme complex that silences tumor-suppressor genes. EZH2, the catalytic engine of PRC2, is overexpressed in many cancers, including B-cell lymphoma. The study found PQQ selectively slowed the growth of B-cell lymphoma cells in laboratory conditions, outperforming its effects on other cancer cell lines. Biochemical assays, cell-based experiments, and molecular docking all supported PQQ's direct inhibition of PRC2 methyltransferase activity. Because PQQ is already approved as a nutritional supplement in the US, these findings open a potentially accessible avenue for epigenetic cancer therapy, though human clinical evidence is entirely absent at this stage.
Detailed Summary
Epigenetic dysregulation is a hallmark of many cancers, and the enzyme complex PRC2 sits at the center of this problem. PRC2 catalyzes a chemical modification — tri-methylation of histone H3 at lysine 27 — that silences genes, including those that normally suppress tumor growth. Its catalytic subunit, EZH2, is overexpressed in a wide range of human cancers and is considered a validated oncology drug target. Several EZH2 inhibitors have already reached clinical use, but the search for new, safer, or more accessible inhibitors continues.
In this study, researchers at Xiamen University screened a library of more than 2,000 compounds using a PRC2 enzymatic activity assay. From this screen, pyrroloquinoline quinone (PQQ) emerged as a potent inhibitor of PRC2 methyltransferase activity. PQQ is a naturally occurring redox cofactor found in foods like fermented soybeans and green tea, and it is commercially sold as an antioxidant and neuroprotective supplement in the United States.
The team evaluated PQQ's anticancer effects across multiple tumor cell lines and found it demonstrated particularly strong activity against B-cell lymphoma cells — a cancer type characterized by elevated EZH2 activity. Biochemical assays confirmed direct inhibition of PRC2 enzymatic function, cellular assays showed suppressed proliferation, and molecular docking studies provided a structural rationale for how PQQ interacts with the complex.
These findings are notable because they represent the first reported evidence that a common dietary supplement can selectively target PRC2, offering a potential new angle for anti-lymphoma therapy. The accessibility and established safety profile of PQQ make it an intriguing candidate for further investigation.
However, all experiments were conducted in vitro, meaning in cell cultures rather than living organisms. No animal or human data exist yet, and the leap from lab dish to clinical benefit is substantial. The summary is also based on the abstract only, limiting full methodological assessment.
Key Findings
- PQQ identified as a potent PRC2/EZH2 inhibitor from a screen of over 2,000 compounds.
- PQQ selectively suppressed B-cell lymphoma cell proliferation, which shows elevated EZH2 activity.
- Molecular docking studies provided structural evidence for PQQ's direct binding to PRC2.
- This is the first study to show a dietary supplement can inhibit PRC2 methyltransferase activity.
- PQQ is already FDA-approved as a nutritional supplement, lowering barriers to future clinical study.
Methodology
Researchers used a PRC2 enzymatic activity assay to screen 2,000+ compounds, identifying PQQ as a hit. They then employed biochemical assays, cell proliferation assays across multiple tumor lines, and molecular docking simulations to characterize PQQ's mechanism. All experiments were conducted in vitro.
Study Limitations
All experiments were performed in vitro; no animal models or human trials have been conducted, making clinical translation speculative. The full methodology, dose-response data, and selectivity profiling are not assessable as this summary is based on the abstract only. In vitro anticancer activity frequently does not translate to in vivo efficacy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.